You just read:

Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled

News provided by

Tocagen Inc.

23 Feb, 2017, 08:01 ET